Abstract
In spite of significant efforts in academic and commercial laboratories, major breakthroughs in oral peptide and protein formulation have not been achieved. The major barriers to developing oral formulations for peptides and proteins include poor intrinsic permeability, lumenal and cellular enzymatic degradation, rapid clearance, and chemical and conformational stability. Pharmaceutical approaches to address these barriers, which have been successful with traditional, small, organic drug molecules, have not readily translated into effective peptide and protein formulations. The success achieved by Sandoz with cyclosporin formulations remains one clear example of what can be achieved, although it is likely that effective oral formulations for peptides and proteins will remain highly compound specific. Although the challenges are significant, the potential therapeutic benefit remains high, particularly with the increasing identification of potential peptide and protein drug candidates emerging from the biotechnology arena. Successful formulations will most likely require a systematic and careful merger of formulation and design delivery systems which maximize the potential for absorption across the epithelial cell layer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
M. J. Humphrey and P. S. Ringrose. Peptide and related drugs: A review of their absorption, metabolism, and excretion. Drug Metab. Reviews 17:283–310 (1986).
V. H. L. Lee, A. Yamamoto, and U. B. Kompella. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Systems 8:91–192 (1991).
H. P. Merkle. New aspects of pharmaceutical dosage forms for controlled drug delivery of peptides and proteins. Eur. J. Pharm. Sci. 2:19–21 (1994).
C. Lehr. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Systems 11:119–160 (1994).
J. M. Sarciaux, L. Acar, and P. A. Sado. Using microemulsion formulations for oral drug delivery of therapeutic peptides. Int. J. Pharm. 120:127–136 (1995).
M. J. Humphrey. The oral bioavailability of peptides and related drugs. In S. S. Davis, L. Illum, and E. Thomlinson (eds.), Delivery Systems for Peptide Drugs, pp. 139–151, 1986, Plenum Press, New York.
V. H. L. Lee. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carrier Systems 5:69–97 (1988).
S. Yoshioka, L. Caldwell, and T. Higuchi. Enhanced rectal bioavailability of polypeptides using sodium 5-methoxysalicylate as an absorption promoter. J. Pharm. Sci. 71:593–597 (1982).
J. C. Scott-Moncrieff, Z. Shao, and A. K. Mitra. Enhancement of intestinal insulin absorption by bile salt-fatty acid mixed micelles in dogs. J. Pharm. Sci. 83:1465–1469 (1994).
M. J. Cho, J. F. Scieszka, and P. S. Burton. Citric acid as an adjuvant for transepithelial transport. Int. J. Pharm. 52:79–81 (1989).
S. Muranishi, Y. Tokunaga, K. Taniguchi, and H. Sezaki. Potential absorption of heparin from the small intestine and the large intestine in the presence of monoolein mixed micelles. Chem. Pharm. Bull. 25:1159–1163 (1977).
J. A. Fix, K. Engle, P. A. Porter, P. S. Leppert, S. J. Selk, C. R. Gardner, and J. Alexander. Acylcarnitines: drug absorption-enhancing agents in the gastrointestinal tract. Am. J. Physiol. 251:G332–G340 (1986).
Z. Shao, Y. Li, R. Krishnamoorthy, T. Chermak, and A. K. Mitra. Differential effects of anionic, cationic, nonionic, and physiologic surfactant on the dissociation, chymotrypsin degradation, and enteral absorption of insulin hexamers. Pharm. Res. 10:243–250 (1993).
P. P. Constantinides, J. Scalart, C. Lancaster, J. Marcello, G. Marks, H. Ellens, and P. L. Smith. Water-in-oil microemulsions containing medium-chain glyceride: Formulation and absorption evaluation in rat. Proc. Int. Symp. Control. Release Bioactive Mater. 20:184–185 (1993).
E. Bjork, U. Isaksson, P. Edman, and P. Artursson. Starch microspheres induce pulsatile delivery of drugs and peptides across the epithelial barrier by reversible separation of tight junctions. J. Drug Targeting 2:501–507 (1995).
J. A. Fix. Strategies for delivery of peptides utilizing absorption enhancing agents. Meeting Abstract, Conf. on Formulations and Drug Delivery, ACS, Boston (1995).
M. Mesiha and M. Sidhom. Increased oral absorption enhancement of insulin by medium viscosity hydroxypropyl cellulose. Int. J. Pharm. 114:137–140 (1995).
E. A. Hosny, N. M. Khan Ghilzai, and A. H. Al-Dhawalie. Effective intestinal absorption of insulin in diabetic rats using enteric coated capsules containing sodium salicylate. Drug Devel. Ind. Pharm. 21:1583–1589 (1995).
G. Fricker and J. Drewe. Enteral absorption of octreotide: Modulation of intestinal permeability by distinct carbohydrates. J. Pharmacol. Exp. Ther. 274:826–832 (1995).
J. P. F. Bai and G. L. Amidon. Degradation of insulin by trypsin and alpha-chymotrypsin. Pharm. Res. 9:969–978 (1992).
P. Buhlmayer, A. Caselli, W. Fuhrer, R. Goschkler, V. Rasetti, H. Rueger, J. L. Stanton, L. Criscione, and J. M. Wood. Synthesis and biological activity of some transition state inhibitors of human renin. J. Med. Chem. 31:1839 (1988).
A. Yamamato, T. Taniguchi, K. Rikyuu, T. Tsuji, T. Fujita, M. Murakami, and J. Muranishi. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11:1496–1500 (1994).
V. H. L. Lee. Protease inhibitors and penetration enhancers as approaches to modify peptide absorption. J. Controlled Rel. 13:213–223 (1991).
S. Fuiji, T. Yokohama, K. Ikegaya, F. Sato, and N. Yohoo. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J. Pharm. Pharmacol. 37:545–549 (1985).
A. T. Florence, A. M. Hillery, N. Hussain, and P. U. Jani. Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate. J. Controlled Rel. 36:36–46 (1995).
P. P. Constantinides, C. M. Lancaster, J. Marcello, D. C. Chiossone, D. Orner, I. Hildalgo, P. L. Smith, A. B. Sarkahian, S. H. Yiv, and A. J. Owen. Enhanced intestinal absorption of an RGD peptide from water-in-oil microemulsions of different composition and particle size. J. Controlled Rel. 34:109–116 (1995).
S. Rao and W. A. Ritschel. Colonic drug delivery of small peptides. S.T.P. Pharma Sciences 5:19–29 (1995).
H. Brondsted and J. Kopecek. Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation. Pharm. Res. 9:1540–1545 (1992).
A. Rubinstein, R. Radai, M. Ezra, S. Pathak, and J. S. Rokem. In vitro evaluation of calcium pectinate: a potential colonic-specific drug delivery carrier. Pharm. Res. 10:258–263 (1993).
J. P. F. Bai and L. L. Chang. Transepithelial transport of insulin: I. Insulin degradation by insulin-degrading enzyme in small intestinal epithelium. Pharm. Res. 12:1171–1175 (1995).
Y. Taki, T. Sakane, T. Nadai, H. Sezaki, G. L. Amidon, P. Langguth, and S. Yamashita. Gastrointestinal absorption of peptide drug: Quantitative evaluation of the degradation and the permeation of metkephamid in rat small intestine. J. Pharmacol. Exp. Ther. 274:373–377 (1995).
V. H. L. Lee, S. Dodda-Kashi, G. M. Grass, and W. Rubas. Oral route of peptide and protein drug delivery. In V. H. L. Lee (ed.), Protein and Peptide Drug Delivery, pp. 691–738, 1991, Dekker, New York.
L. Hovgaard, E. J. Mack, and S. W. Kim. Insulin stabilization and GI absorption. J. Controlled Rel. 19:99–108 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fix, J.A. Oral Controlled Release Technology for Peptides: Status and Future Prospects. Pharm Res 13, 1760–1764 (1996). https://doi.org/10.1023/A:1016008419367
Issue Date:
DOI: https://doi.org/10.1023/A:1016008419367